Font

Aa Aa Aa

Background color

A A

Site version

Color Black and white

Amiodarone-Darnitsa

Class III antiarrhythmic agents

Composition. Active substance: amiodarone.

Preventing recurrence of:

– Life-threatening ventricular tachycardia (Amiodarone-Darnitsa can only be administered in a hospital setting under observation)
– Documented symptomatic and disabling ventricular tachycardia
– Documented supraventricular tachycardia, if the need to prescribe the drug is established in patients with a condition that is resistant to other therapies or with contraindications to other methods of treating ventricular fibrillation

Treatment of supraventricular tachycardia: slowing or reducing atrial fibrillation or flutter.

Amiodarone can be used in patients with ischemic heart disease and/or left ventricular dysfunction (see the Pharmacodynamics Section).

In adults, the drug is taken orally, during or after a meal, without chewing, with a small amount of liquid.

Initial treatment.

The usual dosing regimen is 3 tablets per day for 8 to 10 days.

In some cases, higher doses can be used for initial treatment (4 to 5 tablets per day), but always for a short period and under ECG monitoring.

Maintenance treatment.

The minimum effective dose should be determined; it may vary depending on the patient from 0.5 tablets per day (1 tablet per 2 days) to 2 tablets per day.

Children.

The safety and efficacy of amiodarone in children have not been assessed, so using the drug in children is not recommended.

1
...
1
2
3
...
0
Specialized edition for medical institutions and doctors.